189 views•Jan 14, 2021
https://www.youtube.com/watch?v=MPYnd15ZNdg&feature=emb_logo
Soar Financial
1.4K subscribers
Moneta Porcupine Mines (TSX:ME) is acquiring the Garrison project lifting the resource base to 8.5mn oz Au. We catch up with CEO O'Connor.
??? EXPAND FOR MORE INFORMATION ???
#SFLive Breaking News Special
Moneta Porcupine Mines Inc. (TSX: ME)
Guest: Gary O'Connor, President & CEO
Originally live streamed on January 14th, 2020 at 11:00am PST.
www.twitter.com/soarfinancial - make sure to follow us & click on the ??
Press Release, January 14th, 2021:
MONETA TO ACQUIRE GARRISON PROJECT FROM O3 MINING TO CREATE A LEADING CANADIAN GOLD DEVELOPMENT COMPANY WITH 4.0M OZ GOLD INDICATED AND 4.4M OZ GOLD INFERRED
Link: https://www.monetaporcupine.com/monet...
?? Follow Us! ??
?? Twitter: http://twitter.com/soarfinancial
?? Instagram: https://www.instagram.com/soarfinancial/
?? Facebook: https://www.facebook.com/soarfinancial/
?? Website: http://www.soarfinancial.com
SF Live is a new format by Soar Financial Partners. The goal is to give short company updates and more importantly get investors engaged directly with the companies.
Intro Music: "Summer" by Bensound.com
https://investorshub.advfn.com/Moneta-Porcupine-Mines-Inc-TSX-ME-5495/
God Bless
Recent ME News
- 23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel • GlobeNewswire Inc. • 06/28/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:17:11 PM
- 23andMe Launches New Genetic Report on Bipolar Disorder • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- 23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community • GlobeNewswire Inc. • 06/04/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:06:02 PM
- 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:06:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 09:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:07:02 PM
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results • GlobeNewswire Inc. • 05/23/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:07:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:06:05 PM
- Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:06:05 PM
- 23andMe to Report Q4 and Full Year FY2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:50:07 PM
- Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case • Business Wire • 04/30/2024 03:00:00 PM
- 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 08:05:00 PM
- 23andMe announces CEO’s intention to pursue a potential take-private • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- 23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 04/05/2024 08:05:00 PM
- 23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 • GlobeNewswire Inc. • 03/20/2024 11:30:00 AM
- 23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- 23andMe Launches New Genetic Reports on Common Forms of Cancer • GlobeNewswire Inc. • 03/06/2024 12:30:00 PM
- 23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:36:48 PM
FEATURED BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • Jul 2, 2024 7:19 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM